Although this approach includes some tumor specific reactivities, there is still overwhelming alloreactivity to other HLA molecules, since T cells will also be selected on other mouse MHC molecules and react to the non-HLA-A2 human alleles. This evidence concerns the gene HLA-C and neoplasm.